This is the result of my liver biposy. Any insights on the comment?
-----
CLINICAL HISTORY>>:: Prostate Ca with hepatic mets ?Small cell transformation versus other.
FINAL DIAGNOSIS>>:: LIVER NODULE, CORE BIOPSY: - POORLY DIFFERENTIATED PROSTATIC ADENOCARCINOMA WITH SMALL CELL TRANSFORMATION. GW/vn
Comment: The tumor cells are positive for TTF1 and AR, focally positive for NKX3.1 and INSM1, negative for PSA and Synaptophysin. Ki67 stains over 90% of the tumor cells.
-----
My guess is that the comment explains what was found and supports the final diagnosis.
Is there anything actionable in this?
Written by
skiingfiend
To view profiles and participate in discussions please or .
I asked chatGPT to explain the biopsy results in laymen's language, here's what I got:
The phrase "POORLY DIFFERENTIATED PROSTATIC ADENOCARCINOMA WITH SMALL CELL TRANSFORMATION" describes the type and characteristics of the cancer identified in the liver nodule biopsy.
1. Prostatic adenocarcinoma: This indicates that the cancer originated in the prostate gland and is of the adenocarcinoma type. Adenocarcinoma is the most common type of prostate cancer and arises from the glandular cells of the prostate.
2. Poorly differentiated: This term suggests that the cancer cells appear abnormal and do not closely resemble normal prostate cells under the microscope. Poorly differentiated cancers tend to grow and spread more aggressively than well-differentiated cancers.
3. Small cell transformation: Small cell transformation refers to a change in the characteristics of the cancer cells, where they acquire features similar to small cell carcinoma. Small cell carcinoma is a type of cancer that typically arises in the lungs but can also occur in other organs. Small cell transformation often indicates a more aggressive behavior of the cancer.
In summary, the diagnosis indicates that the cancer in the liver nodule originated from the prostate gland, but it has undergone a transformation into a more aggressive subtype characterized by poorly differentiated features and small cell transformation. This information is crucial for guiding further treatment decisions and assessing prognosis.
The Ki67 result indicates the proliferation rate of the tumor cells, meaning how quickly they are dividing and growing. In this case, the Ki67 staining showed that over 90% of the tumor cells are actively dividing and multiplying, which suggests that the cancer is highly aggressive and likely to grow rapidly.
"Focally positive" means that only some of the tumor cells are showing positivity for NKX3.1 and INSM1, indicating that not all cells are expressing these markers.
"Negative" for PSA and Synaptophysin means that the tumor cells do not show any expression of these markers.
In summary, while some cells within the tumor are expressing NKX3.1 and INSM1, none of the tumor cells are expressing PSA or Synaptophysin. These markers help characterize the type and behavior of the cancer cells.
The markers provide valuable information about the characteristics of the cancer cells:
1. NKX3.1: This marker is typically found in prostate cells and is often used to identify prostate cancer. Its focal positivity suggests that some of the cancer cells still retain characteristics of prostate cells.
2. INSM1: This marker is associated with neuroendocrine cells, which are often present in small cell carcinoma. The focal positivity for INSM1 indicates that some of the cancer cells have transformed into a neuroendocrine phenotype, consistent with the small cell transformation observed in the biopsy.
3. PSA (Prostate-Specific Antigen): PSA is a protein produced by normal prostate cells. Negative staining for PSA indicates that the cancer cells have lost their normal prostate cell characteristics and are not producing this protein.
4. Synaptophysin: This marker is also associated with neuroendocrine cells and is often used to identify neuroendocrine tumors. The negative staining for Synaptophysin further supports the presence of neuroendocrine features in the cancer cells.
Overall, these markers help pathologists and oncologists better understand the nature of the cancer cells, their origin, and potential treatment options.
The finding of focal positivity for INSM1 but negativity for Synaptophysin suggests that while some of the cancer cells express INSM1, a marker associated with neuroendocrine cells, they do not express Synaptophysin, another marker commonly found in neuroendocrine tumors.
This discrepancy could indicate a heterogeneous population of cancer cells within the tumor, where only certain cells express INSM1, while others do not express either marker. Alternatively, it could suggest a specific subtype of neuroendocrine differentiation that does not involve Synaptophysin expression.
Ultimately, the presence of INSM1 positivity indicates some level of neuroendocrine differentiation within the tumor, which may have implications for treatment and prognosis, but further investigation and evaluation would be needed to fully understand the significance of these findings.
The statement "The tumor cells are positive for TTF1 and AR" means that the tumor cells are expressing two specific proteins: TTF1 (Thyroid Transcription Factor 1) and AR (Androgen Receptor).
1. TTF1: This protein is commonly found in lung and thyroid cancers. Its presence in the tumor cells could suggest a potential origin from these tissues or indicate a phenomenon known as lineage plasticity, where cancer cells acquire characteristics of other cell types.
2. AR: Androgen Receptor is a protein that plays a key role in prostate cancer. Its presence in the tumor cells suggests that they may be responsive to androgen signaling, which is important for the growth and progression of prostate cancer.
Interpreting these findings for prognosis can be complex and depends on various factors such as the extent of disease, treatment history, and other molecular characteristics of the tumor. In general:
- Expression of AR in prostate cancer is often associated with hormone sensitivity, meaning that treatments targeting androgen signaling pathways, such as hormone therapy, may be effective.
- However, the presence of TTF1 in prostate cancer can be associated with a more aggressive subtype of the disease or resistance to certain treatments.
Ultimately, the interpretation of these findings for prognosis would require consultation with a medical oncologist or pathologist who can integrate this information with other clinical and molecular data to develop an individualized treatment plan and prognosis for the patient.
It's chatGPT 3.5, their free web version: chat.openai.com/?sso=The thoroughness of the analysis was prompted by some of my probing questions. It really did a great job explaining the results.
I shared the BCXL701 idea with my MO and he had the following opinion:
Overall, the data looks encouraging, with tumour shrinkage seen even in patients that have had prior exposure to platinum drugs (i.e. cisplatin and carboplatin). The patients numbers are too small to make any grand conclusions, but the treatment seems to be generally well tolerated. It would be good to see updated efficacy data from the group as it evolves. Definitely would put this on the list of potentials to track.
_____
You need a big monitor (28+ in to zoom and see the poster clearly).
I've never been to New York, so no experience here. However you seem to have intimate knowledge of the in and outs of the changing character of the different neighbourhoods. 🤡🤡
Ok, I'll let you have the last word, make it good.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
CRPC - causes and prevention of 
I got the answer of My Right Kidney Biopsy 
Bone met biopsy = [b]PSMA-POSITIVE, PSA-NEGATIVE TUMOR[/b]
